Bladder Cancer Coverage from Every Angle

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on Urothelial, RCC, and Other GU Malignancies: Two Key Trials

Posted: Tuesday, September 12, 2017

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss study findings on cabozantinib plus nivolumab and cabozantinib-nivolumab plus ipilimumab in patients with metastatic urothelial carcinoma and other genitourinary tumors; and lenvatinib plus pembrolizumab in patients with renal cell carcinoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.